Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807562671> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W2807562671 endingPage "36" @default.
- W2807562671 startingPage "31" @default.
- W2807562671 abstract "Background In phase III trials, rivaroxaban demonstrated non-inferiority over enoxaparin/warfarin to prevent recurrent venous thromboembolism (VTE), with a reduction of major bleeding. However, compared to provoked VTE, the risk-benefit ratio of rivaroxaban may be different for patients with unprovoked VTE. Methods In a retrospective claims data analysis using US MarketScan claims from 1/2012 to 12/2016, we included adults with a primary diagnosis of VTE newly-initiated on rivaroxaban or warfarin within 30-days of the incident VTE and with ≥12-months of continuous insurance benefits prior to the VTE (baseline). Patients with provoked VTE, a claim for anticoagulation during baseline or who redeemed prescriptions for ≥1 oral anticoagulant were excluded. Our primary outcomes were recurrent VTE and major bleeding at 6-months using an intention-to-treat (ITT) analysis. Three-month ITT and 12-month on-treatment (30-day permissible gap) analyses were also performed. Inverse probability-of-treatment weights based on propensity-scores and Cox regression were used to compare outcomes. Findings We identified 10,489 rivaroxaban users and 26,364 warfarin users with incident unprovoked VTE. At 6-months, rivaroxaban was associated with a hazard ratio (HR) of 0.60 (95% confidence interval [CI] = 0.54–0.67) for recurrent VTE (number-needed-to-treat: 59; 95%CI 49–76) and a HR = 0.80 (95% CI = 0.66–0.98) for major bleeding versus warfarin. Our findings remained consistent in the 3- and 12-month analyses. Interpretation Consistent with the results from the EINSTEIN phase-III trials, findings of our routine practice study suggest that, in patients with unprovoked VTE, rivaroxaban has the potential to reduce both the risk of major bleeding and recurrent VTE compared to warfarin." @default.
- W2807562671 created "2018-06-13" @default.
- W2807562671 creator A5004003194 @default.
- W2807562671 creator A5005652290 @default.
- W2807562671 creator A5034742104 @default.
- W2807562671 creator A5061718836 @default.
- W2807562671 date "2018-08-01" @default.
- W2807562671 modified "2023-10-06" @default.
- W2807562671 title "Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study" @default.
- W2807562671 cites W2012519169 @default.
- W2807562671 cites W2016362027 @default.
- W2807562671 cites W2028788632 @default.
- W2807562671 cites W2036193982 @default.
- W2807562671 cites W2073700468 @default.
- W2807562671 cites W2079491969 @default.
- W2807562671 cites W2110891636 @default.
- W2807562671 cites W2117662968 @default.
- W2807562671 cites W2134430286 @default.
- W2807562671 cites W2160625453 @default.
- W2807562671 cites W2163278718 @default.
- W2807562671 cites W2164595809 @default.
- W2807562671 cites W2186520609 @default.
- W2807562671 cites W2225295868 @default.
- W2807562671 cites W2225937646 @default.
- W2807562671 cites W2273849032 @default.
- W2807562671 cites W2468651875 @default.
- W2807562671 cites W2489373475 @default.
- W2807562671 cites W2536636209 @default.
- W2807562671 cites W2545663848 @default.
- W2807562671 cites W2545724835 @default.
- W2807562671 cites W2556140266 @default.
- W2807562671 cites W2595355654 @default.
- W2807562671 cites W2606733053 @default.
- W2807562671 cites W2612251907 @default.
- W2807562671 doi "https://doi.org/10.1016/j.thromres.2018.05.031" @default.
- W2807562671 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29883907" @default.
- W2807562671 hasPublicationYear "2018" @default.
- W2807562671 type Work @default.
- W2807562671 sameAs 2807562671 @default.
- W2807562671 citedByCount "12" @default.
- W2807562671 countsByYear W28075626712018 @default.
- W2807562671 countsByYear W28075626712019 @default.
- W2807562671 countsByYear W28075626712020 @default.
- W2807562671 countsByYear W28075626712021 @default.
- W2807562671 countsByYear W28075626712022 @default.
- W2807562671 countsByYear W28075626712023 @default.
- W2807562671 crossrefType "journal-article" @default.
- W2807562671 hasAuthorship W2807562671A5004003194 @default.
- W2807562671 hasAuthorship W2807562671A5005652290 @default.
- W2807562671 hasAuthorship W2807562671A5034742104 @default.
- W2807562671 hasAuthorship W2807562671A5061718836 @default.
- W2807562671 hasConcept C126322002 @default.
- W2807562671 hasConcept C167135981 @default.
- W2807562671 hasConcept C17923572 @default.
- W2807562671 hasConcept C201903717 @default.
- W2807562671 hasConcept C207103383 @default.
- W2807562671 hasConcept C2776301958 @default.
- W2807562671 hasConcept C2778205648 @default.
- W2807562671 hasConcept C2778661090 @default.
- W2807562671 hasConcept C2779161974 @default.
- W2807562671 hasConcept C44249647 @default.
- W2807562671 hasConcept C50382708 @default.
- W2807562671 hasConcept C71924100 @default.
- W2807562671 hasConcept C72563966 @default.
- W2807562671 hasConceptScore W2807562671C126322002 @default.
- W2807562671 hasConceptScore W2807562671C167135981 @default.
- W2807562671 hasConceptScore W2807562671C17923572 @default.
- W2807562671 hasConceptScore W2807562671C201903717 @default.
- W2807562671 hasConceptScore W2807562671C207103383 @default.
- W2807562671 hasConceptScore W2807562671C2776301958 @default.
- W2807562671 hasConceptScore W2807562671C2778205648 @default.
- W2807562671 hasConceptScore W2807562671C2778661090 @default.
- W2807562671 hasConceptScore W2807562671C2779161974 @default.
- W2807562671 hasConceptScore W2807562671C44249647 @default.
- W2807562671 hasConceptScore W2807562671C50382708 @default.
- W2807562671 hasConceptScore W2807562671C71924100 @default.
- W2807562671 hasConceptScore W2807562671C72563966 @default.
- W2807562671 hasFunder F4320307771 @default.
- W2807562671 hasLocation W28075626711 @default.
- W2807562671 hasLocation W28075626712 @default.
- W2807562671 hasOpenAccess W2807562671 @default.
- W2807562671 hasPrimaryLocation W28075626711 @default.
- W2807562671 hasRelatedWork W1964152230 @default.
- W2807562671 hasRelatedWork W2022044594 @default.
- W2807562671 hasRelatedWork W2026094606 @default.
- W2807562671 hasRelatedWork W2071306276 @default.
- W2807562671 hasRelatedWork W2611840721 @default.
- W2807562671 hasRelatedWork W2980864243 @default.
- W2807562671 hasRelatedWork W3187162536 @default.
- W2807562671 hasRelatedWork W4210827470 @default.
- W2807562671 hasRelatedWork W4383295089 @default.
- W2807562671 hasRelatedWork W4384497977 @default.
- W2807562671 hasVolume "168" @default.
- W2807562671 isParatext "false" @default.
- W2807562671 isRetracted "false" @default.
- W2807562671 magId "2807562671" @default.
- W2807562671 workType "article" @default.